Abstract
In the wake of Hong Kong’s zero-COVID policy, this study comprehensively analyses the epidemiological shift in respiratory viruses among hospitalized pediatric patients. The research leverages a unique natural experiment created by the policy’s stringent measures, which led to a significant reduction in virus circulation from 2020 to early 2023. The study highlights two distinct periods: pre-COVID-19 and post-mask mandate. We used pediatric hospitalization records from January 2015 to December 2019 and March 2023 to February 2024 to reveal a notable rebound in respiratory viruses. The age-stratified analysis indicated a shift in virus susceptibility. The odds ratio of having a co-infection was significantly increased in hospitalized children aged <1 to 12 years old during the post-COVID-19 mask mandate. Moreover, the adenovirus infection in younger children was more prominent, while RSV expanded its prevalence to older children aged>6 years old and raised health concerns. The study underscores the potential long-term impacts of interrupted virus exposure on children’s immune development and the need for vigilant monitoring of respiratory virus trends. It calls for further research to elucidate the causal relationships between SARS-CoV-2 exposure, subsequent respiratory virus susceptibility, and the implications for paediatric health in the post-pandemic era.
Highlights
- Children (4.37 ± 0.05 years old) hospitalized after COVID-19 and tested for respiratory viruses were significantly older than those (3.49 ± 0.03 years old) before COVID-19.
- The odds ratio of having a co-infection was significantly increased in hospitalized children aged <1 to 12 years old during the post-COVID-19 era.
- In the post-COVID-19 era, the adenovirus infection in younger children was more prominent while RSV expanded its prevalence to older children aged>6 years old
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Clincial Research Ethics Committee (CREC) of The Joint The Chinese University of Hong Kong (CUHK) and New Territories East Cluster (NTEC) gave ethical approval Ref: 2019.120 and 2022.612 for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
